Drugmaker Tubilux Pharma manufactured products in conditions that risked contamination and failed to properly test its products before release, according to the FDA. Source: Drug Industry Daily

The FDA plans to examine if substantive risk information about a drug can be effectively communicated via character-limited social media platforms like Twitter or if just a link will do.…

Any major changes to the way the 340B drug discount program is regulated and overseen will require action from Congress, experts told a House subcommittee Tuesday. Source: Drug Industry Daily

A Senate Appropriations subcommittee on Tuesday approved a bill that would provide $2.8 billion in discretionary funding for the FDA in fiscal 2018. Source: Drug Industry Daily

FDA Commissioner Scott Gottlieb expanded on his drug competition action plan at a day-long agency meeting on generic competition Tuesday. To make the process more transparent, the agency is considering…